The use of mTOR inhibitors and SESN2 expression vectors in this study clearly demonstrated that SESN2 promotes glycolysis in pancreatic cancer through the mTOR signaling pathway (Figure 3) [73]. The gene discussed is SESN2; the disease is pancreatic neoplasm.